Category Archives: Induced Pluripotent Stem Cells

Bloomberg Philanthropies, Johns Hopkins University School of Medicine, and The New York Stem Cell Foundation Research Institute Announce an…

NEW YORK, Oct. 22, 2019 /PRNewswire/ -- Bloomberg Philanthropies, Johns Hopkins University School of Medicine (JHUSOM), and The New York Stem Cell Foundation (NYSCF) Research Institute today announced an initiative to fundamentally advance and expand the science of precision medicine, in which diagnostic disease markers are defined with pinpoint accuracy to help researchers understand disease pathways and customize therapeutic approaches. The collaboration will combine the renowned clinical and medical expertise of Johns Hopkins with the unique stem cell technologies and research capabilities of the NYSCF Research Institute to accelerate Hopkins' pioneering Precision Medicine Initiatives.

"Johns Hopkins is working intensively to realize the great promise of precision medicine for all those in our care, locally and globally," said Johns Hopkins President Ronald J. Daniels. "This significant new collaboration with Bloomberg Philanthropies and NYSCF moves us ever closer to that aim as we join together our far-reaching research capacities to advance knowledge and deliver better health outcomes for populations and people around the world."

This collaboration will also establish an unprecedented cache of human disease models available to researchers worldwide thus promoting the real world application of precision medicine and driving a new paradigm for understanding and improving the approach to human disease.

"Bloomberg Philanthropies' mission is to ensure better, longer lives for the greatest number of people," said Michael R. Bloomberg, founder of Bloomberg LP and Bloomberg Philanthropies. "For years, Johns Hopkins University and the New York Stem Cell Foundation have shared that mission and we're honored to deepen our partnerships with them as they explore new, innovative ways to save lives through the application of precision medicine."

Diseases manifest themselves differently in different patients. To understand the basis of these differences and to tailor treatments for specific patients, researchers need more accurate biological tools. Stem cell models provide a "biological avatar" of the patient from which they were created, allowing scientists and clinicians to better understand, define, and account for differences in individual patients and groups of patients.

The new initiative will use induced pluripotent stem cells to study disease characteristics in subgroups of patients, identifying markers that lead to varying disease manifestations. For example, by examining stem cells from seemingly similar patients with different forms of multiple sclerosis, we may be able to better understand the full range of disease mechanisms and pathways.

The Johns Hopkins Precision Medicine Initiative already includes 16 Precision Medicine Centers of Excellence (PMCOE), each focusing on a specific disease, and is now working to develop 50 Precision Medicine Centers in the next five years. Johns Hopkins believes that this advancement in the study and application of precision medicine has the potential to transform the diagnosis and management of many diseases.Often, what is now categorized as a single disease is actually made up ofmultiple diseases that display similar symptoms, but require quite different therapies. Using a wide range of data sources, precision medicine seeks to better elucidate these differences, so that doctors can treat patients with precisely targeted therapies. At Johns Hopkins, dozens of researchers are bringing this idea to reality across a spectrum of debilitating and life-altering diseases.

In this collaboration, the process will begin with the full consent of patients in JHUSOM PMCOEs who wish to participate. Biological samples from the JHUSOM PMCOEs will be collected by the NYSCF Research Institute where scientists will create stem cell models of disease using the NYSCF Global Stem Cell Array, the world's first end-to-end automated system for generating human stem cells in a parallel, highly controlled process.Integrating robotics and machine learning, NYSCF's technology reprograms skin or blood cells into stem cells, differentiates them into disease-relevant cell types, and performs genome editing to unravel the genetic basis of disease.

"The NYSCF Research Institute has invented and scaled the most advanced methods of human cell manipulation, which is critical for studying disease at the level of the individual patient," explained NYSCF CEO Susan L. Solomon. "By combining our capabilities with Johns Hopkins' extensive clinical data and expertise, we will be able to develop effective, personalized therapies for patients suffering from diseases with a high unmet need."

The stem cells generated by NYSCF will be used to research and drive effective therapeutic and diagnostic development in a wide range of diseases that include, but are not limited to, Multiple Sclerosis, Alzheimer's, chronic renal failure, and cancers of the lung, breast, prostate, pancreas, and bladder. These stem cell lines will reside in the NYSCF Repository and serve as an extraordinary resource in perpetuity for the disease research community. This vast collection will allow scientists unprecedented insights into the biochemical and genetic mechanisms underlying different diseases and subtypes thereof, thereby illuminating avenues for effective, tailored interventions.

"Stem cell science holds enormous potential for the treatment of a wide range of diseases," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "By combining this approach with Johns Hopkins' groundbreaking work on precision medicine, we are creating a scientific powerhouse that will help us advance medicine and science at an even faster pace. I am excited to see the discoveries and innovations that will be produced by this collaboration."

About Bloomberg PhilanthropiesBloomberg Philanthropies invests in 510 cities and 129 countries around the world to ensure better, longer lives for the greatest number of people. The organization focuses on five key areas for creating lasting change: Arts, Education, Environment, Government Innovation, and Public Health. Bloomberg Philanthropies encompasses all of Michael R. Bloomberg's giving, including his foundation and personal philanthropy as well as Bloomberg Associates, a pro bono consultancy that works in cities around the world. In 2018, Bloomberg Philanthropies distributed $767 million. For more information, please visitbloomberg.orgor follow us on Facebook, Instagram, YouTube, and Twitter.

About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 180 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in developing pioneering stem cell technologies, including the NYSCF Global Stem Cell Array and in manufacturing stem cells for scientists around the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit http://www.nyscf.org or follow us on Twitter, Facebook, and Instagram.

Press Contacts:

The New York Stem Cell Foundation Research Institute David McKeon dmckeon@nyscf.org 212-365-7440

Johns Hopkins University School of Medicine Vanessa Wasta wasta@jhmi.edu

SOURCE The New York Stem Cell Foundation

Home

Read more:
Bloomberg Philanthropies, Johns Hopkins University School of Medicine, and The New York Stem Cell Foundation Research Institute Announce an...

ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services – PharmiWeb.com

Vancouver, Canada, October 21, 2019 ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces it has formed a global consortium of a wide range of leading professional and education societies to combat the rise in the number of unproven commercial cell banking services. Full details of the statement can be foundhere.

The consortium partners include the International Society for Stem Cell Research (ISSCR), Society for Immunotherapy of Cancer (SITC), American Society for Transplantation and Cellular Therapy (ASTCT),American Society of Gene & Cell Therapy (ASGCT), European Society for Blood and Marrow Transplantation (EBMT), Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee ISCT-EBMT (JACIE) and the Forum for Innovative Regenerative Medicine (FIRM).

The consortium has been formed following ISCT issuingpatient advice and concern on unproven T-cell preservation services on August 7, 2019. These services include the banking of T-cells, dental cells and cells for the derivation of induced pluripotent stem cells for potential therapeutic uses.

The joint statement from ISCT and the consortium partners includes an agreement on a number of key points. Commercial cell banking services are not supported by current scientific evidence, as opposed to the range of cell therapies such as CAR-T therapies, that follow established approval processes. Additionally, cell banking services cannot claim to know that the cells they preserve today could ever be appropriate for clinical use, could be used by manufacturers, or meet the requirements of many national and international regulatory agencies. As a result, there is no clear pathway to legitimate clinical use. All parties agree offering these services commercially to patients is thus premature, misleading, and drives false hope.

In addition, the ISCT joint statement makes clear that patients, being misled by these services, are thus prevented from giving a full and valid informed consent. Cell banking companies mislead patients in a number of ways, including using tokens of scientific legitimacy that suggest a stronger scientific basis than currently exists. These tokens include endorsements from individuals or scientific advisory boards that might not fully endorse the specific products, links to scientific articles, and references to ongoing clinical trials.

ISCTs raison detre is to lead the industry in supporting scientifically validated cell and gene therapies. As a result, ISCT will continue to welcome all innovations, including cell banking approaches, that increase the number of patients who can benefit from these therapies, said Bruce Levine,President-Elect, ISCT and one of the inventors of CAR-T therapies.However, ISCT also leads industry action on unproven cell therapies and services in the cell and gene sector. This is why ISCT has forged a consortium throughout the industry against the marketing of speculative cell banking services that do not have appropriate pre-clinical, and clinical evidence and a plausible pathway to the clinical use of banked cells. We collectively believe these banks have the potential to be detrimental to the future development of cell and gene therapies.

About ISCT

Established in 1992, ISCT, the International Society for Cell and Gene Therapy is a global society of clinicians, regulators, researchers, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients lives worldwide.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory and Commercialization. Through strong relationships with global regulatory agencies, academic institutions and industry partners, ISCT drives the advancement of research into standard of care.

Comprised of over 1,500 cell therapy experts across five geographic regions and representation from over 50 countries, ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation. For more information about the society, key initiatives and upcoming meetings, please visit:

Read the rest here:
ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services - PharmiWeb.com

Mutations Linked to Huntington’s Increase Cells’ Resistance to Manganese, Study Finds – Huntington’s Disease News

Mutations associated with Huntingtons disease increase nerve cells resistance to high levels of manganese, according to a recent study.

The results of the study, Huntingtons disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent, were published in NeuroToxicology.

Manganese (Mn) is a trace metal that plays a key role in many cellular processes. It is essential in the production of neurotransmitters chemical substances that allow communication between nerve cells and in the regulation of nerve cells metabolism. However, high levels of Mn in the body are associated with neurotoxicity.

Levels of Mn change substantially in different regions of the brain throughout its development. However, it is still unclear if these regional differences could be linked to the fact that certain types of nerve cells may be more sensitive to higher levels of Mn than others at specific time-points during brain development.

Certain neurological disorders have been associated with alterations in brain Mn levels. It has been shown that human and mouse nerve cell precursors containing a genetic mutation associated with Huntingtons disease have limited access to Mn and are more resilient to its neurotoxic effects.

Investigators from Vanderbilt University and their collaborators now set out to explore the sensitivity of different types of neurons at different developmental stages, from patients with Huntingtons disease and healthy individuals (controls), to Mn neurotoxicity.

We hypothesized that there would be differences in Mn sensitivity between lineages and developmental stages, the researchers said.

The team used several lines of human-induced pluripotent stem cells (hiPSCs) fully matured cells that can be reprogrammed back to a stem cell state, where they are able to grow into almost any type of cell from patients and controls to generate neuroprogenitor cells (NPCs).

The NPCs then were cultured in a lab dish with different cocktails of growth factors to differentiate them into distinct types of neurons. Specifically, there were three different types: striatal neurons, which can be found in the striatum, a brain region involved in motor control; cortical neurons, which can be found in the cortex, or the outer layer of the brain; and midbrain dopaminergic neurons, which can be found in the substantia nigra, a brain region involved in the control of voluntary muscle movements.

The researchers then compared sensitivity to Mn neurotoxicity during each developmental time-point for each cell type between the two groups those with and without Huntingtons.

Their findings revealed that striatal and cortical NPCs derived from Huntingtons patients were more resistant to high levels of Mn compared with those that had been obtained from individuals who did not have the disease. These results were similar to those seen in other studies.

Moreover, the investigators found that patient-derived hiPSCs were themselves more resistant to Mn neurotoxicity than their counterparts.

However, at intermediate stages of development, midbrain neurons that had been derived from patients became more sensitive to the toxic effects of Mn.

The researchers said the sensitivity of midbrain NPCs and mature cortical neurons to Mn neurotoxicity was similar in both groups.

Altogether, these findings suggest that the harmful effects of Mn can be influenced by the presence of genetic mutations associated with Huntingtons disease. That, in turn, depends on the particular developmental stages and neuronal cell types.

In conclusion, our findings may provide insight into therapeutic strategies for diseases in which Mn has been shown to play a role such as HD [Huntingtons disease], especially through specific lineage-targeted interventions, the researchers said.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 79

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Read more from the original source:
Mutations Linked to Huntington's Increase Cells' Resistance to Manganese, Study Finds - Huntington's Disease News

Stem Cells Market : Insights Into the Competitive Scenario of the Market – Online News Guru

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

Read this article:
Stem Cells Market : Insights Into the Competitive Scenario of the Market - Online News Guru

‘Rewind Therapeutics’ and Remyelination – SciTech Europa

At Rewind Therapeutics (a start-up company based in Leuven, Belgium), we focus on the development of treatments for neurological diseases. Myelin is the insulation that wraps around neurons, and in turn, helps neurons to work faster and more efficiently. It is also the target of autoimmune attacks in multiple sclerosis (MS), and any damage to myelin is the proximate cause of the symptoms of the disease.

Myelin is formed by glial cells in the brain called oligodendrocytes; oligodendrocytes and their precursors account for about 30% of all the cells in the brain. The brain has a significant capacity to repair myelin when it is damaged. Repair is accomplished by mobilising stem cells called oligodendrocyte precursor cells (OPCs), which can migrate to the location of the myelin damage and differentiate into oligodendrocytes.

Failure of repair is associated with disability in diseases such as MS. The progression of disability in MS (a separate process from the relapses and remission that are the hallmark of the early stages of the disease) is believed to be associated with the brains failure to repair myelin. Myelin repair is a tightly regulated process, with mechanisms that both promote and inhibit repair. By manipulating the inhibitory processes, we hope to remove the brakes so the repair process works more efficiently.

Historically, treatments for neurological diseases have focused on neurons. While neurons are undoubtedly important, they represent perhaps less than half the cells in the brain. What is emerging is the appreciation that cells in the brain other than neurons can be the target for drugs that treat brain disease.

These other cell types include oligodendrocytes (which is what we focus on), but also astrocytes and microglia. New companies are emerging that are focused on developing therapeutics that target these other cells. This includes companies that are developing small molecule therapeutics, a few companies that are making biologics (antibodies) as well as a couple of companies that are focused on cell-based therapies.

MS is the immediate focus of our therapeutic efforts. We know that the disease results from autoimmune attacks on myelin, and these periodic attacks cause the initial symptoms of the disease. Over time, MS is associated with a progressive disability, so that patients are ultimately confined to a wheelchair and have several other disabilities. It is believed that this progressive disability reflects the loss of myelin, and the loss of the normal capacity to repair myelin enhancing that capacity is our goal.

Oligodendrocyte development from OPCs has been studied for many years. We know a lot of the details in cellular and molecular terms, but there are still many unknowns. However, we do have the ability to study oligodendrocytes and their interactions with neurons in experimental models. Some of these models come from rodents, and it is also possible to make oligodendrocytes (and neurons) from human induced pluripotent stem cells (we use both). The use of these models has enabled the field to identify new drug targets, and to test new therapeutics.

The availability of these models enabled compound screening, and several studies published in the last three to four years reported successful repurposing screens where existing drugs were shown to promote remyelination both in vitro and in vivo. Based on these studies, at least one compound (clemastine) was taken into a clinical trial, and the trial demonstrated a successful proof of mechanism. This was the demonstration of a repair effect on the optic nerve, using visual evoked potentials, which suggests that the compound promoted remyelination. So far, no one had demonstrated an effect on a therapeutic endpoint using a remyelination approach.

Although a lot of preclinical work has suggested that manipulation of remyelination targets can improve myelination in animal models, we do not yet know how these effects will translate into clinical effects. We are still trying to learn how to translate observations in animal models into an impact on clinical disease.

The therapeutic goal in MS is to slow progression of the disability associated with the disease. Historically, it has been difficult to develop drugs that slow the progression of neurodegenerative diseases. Indeed, the success in doing this in the pharma industry is essentially zero. This is a challenging goal. However, promoting remyelination is a novel approach to treating neurodegeneration.

Myelin damage is associated with several neurological disease other than MS. There are other autoimmune diseases, such as neuromyelitis optica spectrum disorder, that are conceptually similar to MS but which lack approved therapies. Multiple system atrophy is a progressive neurodegenerative disease where the pathology may originate from alpha synuclein deposits in oligodendrocytes (unlike Parkinsons disease, where the alpha synuclein deposits are in neurons).

In addition to this, there are several leukodystrophies that are characterised by myelin damage. In acute brain injuries (such as stroke and traumatic brain injury), there is clearly damage to myelin. In these other disease areas, it is not yet clear whether remyelination therapies will have a therapeutic effect, but there are many exciting therapeutic areas to explore.

Dr Ian J. Reynolds

CEO

Rewind Therapeutics

+32 (0) 470858910

ian.reynolds@rewindtherapeutics.com

Read more:
'Rewind Therapeutics' and Remyelination - SciTech Europa

Cell Expansion Market is expected to rise at a remarkable CAGR during the Forecast Period 2016 2024 – Space Market Research

Global Cell Expansion Market: Overview

This report on the global cell expansion market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases.

The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global Cell Expansion market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Get Sample Copy of This Report At: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9037&source=atm

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cell expansion market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increase in prevalence of cancer and rare diseases, rise in demand for regenerative and cell-based therapies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Cell Expansion Market: Segmentation

The cell expansion market has segmented into four categories, namely by type of cells, by product, by end-user and by region.

Geographically, the global Cell Expansion market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.

Request for Ask An Analyst About This Report At: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=9037&source=atm

Global Cell Expansion Market: Competitive Landscape

The report also profiles major players in the cell expansion market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GE Healthcare, Danaher Corporation (Pall Corporation), Terumo Corporation, Merck Millipore (Merck KGaA), Octane Biotech, Inc., Thermo Fisher Scientific, Inc., Lonza Group, STEMCELL Technologies, Inc., Becton, Dickinson and Company, Bio-Techne (R&D Systems), Takara Bio, Inc., Cell Signaling Technology, Inc., PeproTech, CellGenix GmbH, Corning Incorporated, Eppendorf AG, and HiMedia Laboratories.

The global cell expansion market is segmented as follows:

Global Cell Expansion Market Revenue, by Type of Cells Human Cells Stem Cells Adult Stem Cells Induced Pluripotent Stem Cells Embryonic Stem Cells Differentiated Cells Animal Cells

Global Cell Expansion Market Revenue, by Product Type Instruments Cell Expansion Supporting Equipment Bioreactors Automated Cell Expansion Consumables Reagents Media Sera Disposables Bioreactor Accessories Tissue Culture Flasks Others

Global Cell Expansion Market Revenue, by End User Hospitals CMO & CRO Biotechnology & Pharmaceutical Companies Academic & Research Institutes

Global Cell Expansion Market Revenue, by Geography North America US Canada Europe UK Germany France Italy Spain Russia Rest of Europe Asia Pacific China Japan Australia & New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East and Africa South Africa GCC Countries Rest of Middle East & Africa

Request For Discount On This Report At https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=9037&source=atm

Read more here:
Cell Expansion Market is expected to rise at a remarkable CAGR during the Forecast Period 2016 2024 - Space Market Research

Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 – News Adopt

Global Induced Pluripotent Stem Cells Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 presents the analytical view of the industry that will enable readers to formulate and develop critical strategies for their businesses future expansion. With this report on Induced Pluripotent Stem Cells market, we are discussing a deep elaboration of several cogent factors that will play a key role in global market development over the coming years. The report studies market growth, trends, consumption figures, and industry structure, product specification, advertising level, and market income, and predicts future growth for the forecast period from 2018 to 2023.

The overall data presented in the market research report has been extracted from reliable and authentic primary and secondary sources to deliver precise and valid information to our esteemed clients. The whole knowledge is based on latest industry news, opportunities, and trends.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report/global-induced-pluripotent-stem-cells-market-2018-by-333303.html#sample

Top Companies in Induced Pluripotent Stem Cells Market are as follows: Fujifilm Holding Corporation, Astellas Pharma Inc, Fate Therapeutics, Inc, Bristol-Myers Squibb Company, ViaCyte, Inc, Celgene Corporation, Aastrom Biosciences, Inc, Acelity Holdings, Inc, StemCells, Inc, Japan Tissue Engineering Co., Ltd, Organogenesis Inc,

This report provides an evaluation, individual revenue, market share, and growth rate of this market in these Top Regions covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Segment Types are as follows: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others

Main applications of this Market are: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine, ,

What is from the offering:

The report offers actionable insights to boost source-to-contract cycle performance in the market. It gives facts about the work to help stakeholders capture earnings as well as expand their company enterprise. This overall data will also help sourcing professionals enhance savings, formulate better strategies, develop sourcing best practices, know supplier and market challenges. The report will provide correct direction to enthusiastic businesses.

Advantages of Global Induced Pluripotent Stem Cells Market Report:

ACCESS FULL REPORT: https://www.fiormarkets.com/report/global-induced-pluripotent-stem-cells-market-2018-by-333303.html

Moreover, the report studies the Induced Pluripotent Stem Cells industry along with the import and export statistics, industry chain in the market as well as dynamics of demand and supply, product/service specifications, manufacturing capacities, productive manufacturing methods. The present scenario and the expansion likelihood of the market for 2018-2023 are covered in this report.

The report also evaluates the growth established by the market during the forecast period and research conclusions are offered. In addition, the report features innovation offerings, product diagrams, corporate plans, enterprise profile, and financial execution.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Arash is the chief editor of News Adopt. He handles the responsibility of covering Technology news. Arash has a rich experience of 15 years in covering technology news. He is also an Adjunct Professor at the University of Southern California.

Here is the original post:
Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 - News Adopt

New Rett Therapies May Stem From X-chromosome Reactivation Findings – Rett Syndrome News

Genes that are normally silenced in the X-chromosome transition from an off to an on state at different speeds, an event that is dependent on the action of certain proteins and enzymes, according to a recent study.

These findings may one day help design a targeted therapeutic strategy for Rett syndrome and other X-chromosome-linked genetic disorders.

The study, Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming, was published in the journal Genome Research.

Rett syndrome is a rare genetic disorder that affects girls almost exclusively and is characterized by developmental and intellectual disabilities.The condition is caused by mutations in theMECP2 gene, located on the X chromosome, that provides instructions to make a protein called MeCP2. This protein is responsible for maintaining synapses, which are the junctions between nerve cells that allow them to communicate.

Women carry two X chromosomes one from the mother and one from the father while men carry only one, inherited from the mother. To ensure that all genes in the X chromosome are expressed equally in men and women, a process known as X-chromosome inactivation takes place during embryonic development, at which time one of the two X chromosomes carried by females is randomly selected to be inactivated.

A potential way to treat Rett syndrome and other X-chromosome-linked disorders is to devise a strategy to reactivate the healthy copy of the gene on the inactive X-chromosome. This reactivation would occur at the early stages of embryonic growth.

In the study, researchers at KU LeuvenUniversity of Leuven and colleagues used a type of stem cell called induced pluripotent stem cells (iPSCs). These cells are usually derived from adult skin cells (fibroblasts) and behave similarly to embryonic cells, meaning they can give rise to nearly any type of cell in the body.

The team used adult fibroblasts from female mice and reprogrammed them back into iPSCs. Of note, both X chromosomes are active in IPSCs, making these cells a valuable tool to study the mechanisms behind chromosome reactivation.

Working with iPS cells has numerous advantages. Most importantly, when you reprogram female adult cells into iPS cells, both X chromosomes become active again. In other words: X-chromosome reactivation starts happening right under your microscope, Vincent Pasque, assistant professor at KU LeuvenUniversity of Leuven and the studys lead author, said in a news release.

We monitored almost 200 different X-linked genes throughout the X-chromosome reactivation process. What we found is that reactivation happens gradually: different genes require different amounts of time to become active again, said Irene Talon, one of the studys authors.

The researchers found that some genes reactivated early (as early as day 8 after reprogramming), while others took longer. Intermediate genes were reactivated between day 8 and 10, and others between day 10 and 13 (called late genes), while some took longer than 13 days (which were called very late genes).

The reason for the different pace in reactivation, the researchers found, was that the early genes were located closer to genes that escape X-chromosome silencing.

Additionally, these early genes were richer in sites for the binding of transcription factors required for the transition of cells into iPSCs. Of note, transcription factors are proteins that help turn specific genes on or off by binding to nearby DNA.

Specifically, the researchers found that the reactivation timing was dependent on histone deacetylases, which are enzymes that label DNA to be silenced and work like barriers to gene activation.

Our findings suggest that the explanation for this speed difference is a combination of the location of the gene in 3D space on the X chromosome and the role of proteins (transcription factors), and enzymes (histone deacetylases), in particular, Talon added.

X-chromosome reactivation was accompanied by a decrease in the levels of an RNA molecule, called Xist, which is known to be involved in the silencing of the X-chromosome.

Overall, these findings suggest that reactivation of X-linked genes requires the combined action of different players information that is key for the development of possible future therapies for Rett syndrome.

Its important to remember that were talking about very fundamental research here. Contributing to the development of a cure for Rett syndrome and similar disorders is our long-term goal, but it will take us a while to get there, and there are many hurdles to overcome, Pasque said.

We still need to figure out how to use the mechanism for a single gene, how to do it safely in patients, and how to target the right cells in the brain. We do not yet know how to overcome these formidable challenges but we do know that gaining a fundamental understanding of how things work is the crucial first step, he added.

Thats how science works: its a slow process.

Visit link:
New Rett Therapies May Stem From X-chromosome Reactivation Findings - Rett Syndrome News

Stemming the Tide of Alzheimer’s – UCI News

Keith Swayne has a magic touch when it comes to fundraising.

I guess I could go to anyone and get them to write some kind of check just so I would go away, he says, laughing. However, thats not what I want to accomplish. I want to connect people to causes and needs that they can relate to and then help them find a way to help out.

Swayne is so adroit at soliciting donations, in fact, that a campus project he undertook has left people shaking their heads in amazement: His efforts led to a $20 million windfall for investigators at the UCI Institute for Memory Impairments and Neurological Disorders.

Keiths passionate commitment to supporting our research has been tireless and nothing short of transformative, says Joshua Grill, director of UCI MIND.

It all started with a $150,000 gift the Laguna Beach philanthropist made to the research facility in honor of his late wife, Judy, whom he lost to Alzheimers disease in 2014. He also issued a challenge to the community at the time that boosted the donation to $300,000.

The UCI MIND team then leveraged that seed money to secure a total of $20 million in funding from the National Institutes of Health.

Our research is blazing new trails into understanding the genetic, molecular and cellular underpinnings of disease and is poised to lead to identification of new treatment targets and candidates, Grill says. Keiths initial challenge-gift enabled an exponential impact in terms of research support.

Weian Zhao lab at Sue and Bill Gross Stem Cell center at UCI. Lab personnel: Ling Shun, Meglu Han, Michael Toledano, Aude Segaliny, Jan Zimak, Leanne Hildebrand

His late wife would have liked that, Swayne says. The fact that some good came from this terrible disease Judy would certainly want that, he says. And I wanted that too.

The couple, married 50 years, were best friends and committed partners. Judy Swayne, like her husband, was intent on making a difference in her community. Among other contributions, in 1989, she founded the Orange County Community Foundation, which became a major philanthropic institution in the region. Keith Swayne has carried on her legacy as a member of its board, stepping down in September after a stint as chairman.

In addition, Judy Swayne served on numerous nonprofit boards, acted as a role model and mentor to many throughout the philanthropic community, and was the mother of two: a daughter, Anne Keir, who lives in Hawaii, and a son, Kirk Swayne, of Orange County.

The disease was hard on my kids, Keith Swayne says. Its a tough disease.

It was also hard on Swayne himself, Grill notes: Alzheimers is an insidious disorder that robs patients of their most human characteristics language, decision making and, of course, memory.

Ultimately, it also robs patients of their independence, putting a strain on family members.

Keith was a caregiver to his beloved Judy, a costly and taxing role, Grill says. He watched her progress until she succumbed to this unrelenting disease, helpless to do anything to slow or stop its course. He decided to do what he could to prevent others from suffering her fate.

Frank M. LaFerla, dean of the UCI School of Biological Sciences, also recalls Swaynes struggles.

Alzheimers disease really impacted his family, he says. Judy was a very special woman. He wanted to make sure future generations wouldnt experience the pain his wife did.

At the time, LaFerla was director of UCI MIND and talked with Swayne about ways he could make a difference in the search for a cure. One field of research involved stem cells, which experts believe may offer great promise for new medical treatments.

My lab had started getting involved with stem cells many years ago, and about this time a new technology was created using stem cells from your skin, not embryos, LaFerla says. You could take some of a patients skin cells by biopsy and reprogram them to become pluripotent meaning they have the ability to give rise to many different types of cells found in the body, such as brain cells or more skin cells or kidney cells.

Swayne likes innovation and taking chances, LaFerla says: I told him this opportunity was high-risk but had high potential.

That was when Swayne issued his challenge to the community and set about rounding up donors. He held salons at his hillside home, inviting LaFerla and other UCI staffers to speak to local residents. They explained how pluripotent stem cell technology could be used as a tool in Alzheimers research.

I went to people who knew my wife or to people I knew who also had a vested interest in Alzheimers research because they had the disease in their own families, Swayne says.

He found many community members who were willing to contribute.

The odds are that if you live to be 85, theres a 1-in-2 chance youre going to have Alzheimers. A lot of my friends are in my age bracket, says Swayne, 79. The message was compelling.

One thing he learned was that individuals were familiar with the Alzheimers Association but not UCI MIND.

In some respects, UCI MIND is one of the best-kept secrets in Orange County, Swayne says. Many people didnt know that its one of only 30 NIH-designated Alzheimers research centers in the country.

His fundraising zeal and efforts to involve the Orange County community in the effort eventually paid off. As LaFerla says, It worked better than we could ever have dreamed.

When the time came to renew funding for the stem cell research program from the National Institute on Aging, UCI MIND won a five-year commitment to continue its research. One reason behind the NIAs decision: local philanthropic contributions.

With charitable and federal funding in place, UCI established a bank of induced pluripotent stem cells, now a valuable resource for Alzheimers researchers globally. Today, hundreds of cell samples have been provided to investigators at UCI and 10 other research universities around the world, and UCI MIND scientists and their partners have received more than $20 million in grants.

And all of that stemmed, ultimately, from the initial gift we received from Keith, LaFerla says.

Adds Swayne: We grew $150,000 to $20 million. It blows me away.

Hes not resting on his laurels, though. Swayne continues to connect more donors to UCI MIND so that research can progress.

The UCI MIND team is devoted to this cause, he says. Its reassuring to know youve got people with this talent trying to find answers to this disease.

So Swayne writes letters to business and community leaders urging their backing, chairs a panel that seeks new opportunities for philanthropic gifts, speaks on behalf of the institute at public events, and co-leads a caregiver support group for men whose spouses have Alzheimers.

Keith gives a voice to the nearly 6 million Americans with Alzheimers and the more than 15 million caregivers like him, Grill wrote earlier this year in a letter nominating Swayne for the Outstanding Philanthropist Award, which will be conferred on Nov. 14 by the Association of Fundraising Professionals of Orange County in celebration of National Philanthropy Day. UCI MIND would not be the organization it is without the leadership of Keith Swayne.

Read this article:
Stemming the Tide of Alzheimer's - UCI News

Skin-Derived Heart Cells Help Uncover the Genetic Foundations of Cardiac Function – Technology Networks

Genome-wide association studies have uncovered more than 500 genetic variants linked to heart function, everything from heart rate to irregular rhythms that can lead to stroke, heart failure or other complications. But since most of these variations fall into areas of the genome that dont encode proteins, exactly how they influence heart function has remained unclear.

By examining heart cells derived from the skin samples of seven family members, researchers at University of California San Diego School of Medicine have now discovered that many of these genetic variations influence heart function because they affect the binding of a protein called NKX2-5.

NKX2-5 is a transcription factor, meaning it helps turn on and off genes in this case, genes involved in heart development. To do this, NKX2-5 must bind to non-coding regions of the genome. Thats where genetic variation comes in.

NKX2-5 binds to many different places in the genome near heart genes, so it makes sense that variation in the factor itself or the DNA to which it binds would affect that function, said senior author Kelly A. Frazer, PhD, professor of pediatrics and director of the Institute for Genomic Medicine at UC San Diego School of Medicine. As a result, we are finding that multiple heart-related traits can share a common mechanism in this case, differential binding of NKX2-5 due to DNA variants.

The study started with skin samples from seven people from three generations of a single family. The researchers converted the skin cells into induced pluripotent stem cells (iPSCs) as an intermediary. Like all stem cells, iPSCs can both self-renew, making more iPSCs, and differentiate into a specialized cell type. With the right cocktail of molecules and growth factors, the researchers directed iPSCs into becoming heart cells.

These heart cells actually beat in the laboratory dish, and still bear the genetic and molecular features of the individuals from which they were derived.

Frazer and team conducted a genome-wide analysis of these patient-derived heart cells. They determined that NKX2-5 can bind approximately 38,000 sites in the genome. Of those, 1,941 genetic variants affected NKX2-5 binding. The researchers investigated the role of those variants in heart gene function and heart-related traits. One of the genetic variants was associated with the SCN5A gene, which encodes the main channel through which sodium is transported in heart cells.

Since related individuals tend to share similar genetic variants, the team was able to validate their findings by analyzing the same variants in multiple samples.

People typically need a large number of samples to detect the effects of common DNA variants, so we were surprised that we were able to identify with high confidence these effects on NKX2-5 binding at so many sites across the genome with just few people, said first author Paola Benaglio, PhD, a postdoctoral researcher in Frazers lab.

Yet, she said, this finding may just be the tip of the iceberg.

There are probably a lot more genetic variants in the genome involved with NKX2-5 as well as with other important cardiac transcription factors, Frazer said. We identified almost 2,000 in this study, but thats probably only a fraction of what really exists because we were only looking at seven people in a single family and only at one transcription factor. There are probably many more variants in gene regulation sites across the entire population.

Not only does the team plan to further investigate cardiovascular genetics, but they also have their sights set on other organ systems.

We are now expanding this same model system to look at many different transcription factors, across different tissue types, such as pancreas and retina epithelia, and scaling it up to include more families, Benaglio said.

Reference

Benalgio, P. et al. (2019)Allele-specific NKX2-5 binding underlies multiple genetic associations with human electrocardiographic traits. Nature Genetics. DOI:https://doi.org/10.1038/s41588-019-0499-3

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
Skin-Derived Heart Cells Help Uncover the Genetic Foundations of Cardiac Function - Technology Networks